Plain English Summary
Background and study aims
Spinal Cord Stimulation (SCS) is the recommended treatment for severe nerve pain. SCS involves implanting a wire through the skin and into the spine; this then attaches to a battery placed under the skin of the stomach. Electric pulses transmitted via this wire to the nerves provide pain relief. This treatment is only recommended for use in the NHS if patients report pain relief from a ‘trial’ (or test) stimulation where a temporary implanted spine wire is attached to an external battery. The standard practice is for patients to test the system at home for up to 4 weeks. Those experiencing 50% or more pain relief are offered a permanent implanted battery. Although test stimulation is a widely accepted part of clinical practice the scientific evidence for its use is lacking. It is possible that a proportion of patients who fail to experience pain relief during a trial would experience pain relief after a permanent implant. Trials expose patients to an increased risk of infection, pain and increased costs. The aim of this study is to look at the best way to perform the screening trial for patients, either the standard practice or an on-table trial. In the on-table trial patients still have the wires implanted in their back but they try the stimulation in theatre. If they like the sensation, and the painful area is covered with the stimulation, the battery can be implanted at the same time.
Who can participate?
Patients aged 18 and over with persistent pain for more than 6 months who are candidates for SCS
What does the study involve?
Participants are randomly allocated to undergo either the standard practice trial or the on-table trial. Pain, quality of life and costs are assessed by questionnaire at the start of the study and after 3 and 6 months.
What are the possible benefits and risks of participating?
The specific risks for implantation of a Spinal Cord Stimulator are a 0.5% risk of severe headache (known as post-dural puncture headache), a 5% risk of infection and a 10% possibility of the lead moving position or breaking requiring further surgery. Severe complications such as nerve damage are rare. The risks of this surgery are no higher or lower as a result of taking part in the study than anyone else having a spinal cord stimulator implanted.
Where is the study run from?
1. The James Cook University Hospital (UK)
2. Basildon and Thurrock University Hospital (UK)
3. Seacroft Hospital (UK)
When is the study starting and how long is it expected to run for?
July 2015 to May 2020
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
1. Prof. Sam Eldabe
seldabe@nhs.net
2. Morag Brookes
Trial website
Contact information
Type
Scientific
Primary contact
Prof Sam Eldabe
ORCID ID
Contact details
Cheriton House
The James Cook University Hospital
Marton Road
Middlesbrough
TS4 3BW
United Kingdom
Type
Scientific
Additional contact
Miss Morag Brookes
ORCID ID
Contact details
TRIAL-STIM Study Manager
The James Cook University Hospital
Cheriton House
Marton Road
Middlesbrough
TS4 3BW
United Kingdom
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
33619
Study information
Scientific title
Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness?
Acronym
TRIAL-STIM
Study hypothesis
A no SCS screening trial strategy will be clinically superior to a SCS screening trial and more cost-effective.
Ethics approval
North East –Tyne and Wear South Research Ethics Committee, 04/04/2017, ref: 17/NE/0056
Study design
Randomised; Both; Design type: Screening, Device, Psychological & Behavioural, Surgery, Qualitative
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Specialty: Anaesthesia, perioperative medicine and pain management, Primary sub-specialty: Anaesthesia, Perioperative Medicine and Pain Management; UKCRC code/ Disease: Neurological/ Nerve, nerve root and plexus disorders
Intervention
Participants are randomly allocated to groups. Randomisation is achieved by means of a password-protected web-based system developed and maintained by Exeter Clinical Trials Unit (ExeCTU). Once the patient has completed the screening interview and baseline data collection interview, the researcher access the randomisation website using a unique username and password. The website requires entry of the study site, participant initials and participant age before returning the participants’ unique randomisation number and allocation (Engager Intervention or Control). Allocation is stratified by centre and minimised on patient age (>65 or <65years), gender, and presence of failed back surgery syndrome (FBSS) (or not) use of HF10 or not. Allocation concealment is maintained by only revealing allocation of each participant to the study manager following completion of written informed consent and baseline outcomes.
Usual Care: Screening trial and implantation
Participants randomised to this arm receive a screening trial. A screening trial consists of passage of either an external or internalised tunnelled SCS lead or leads attached to an external stimulator as per centre’s routine practice. Those participants that have a successful screening trial receive an implantable neurostimulation system while unsuccessful patients would not receive such an implant. Taking into consideration the RCTs included in the clinical evidence section of NICE TA159, a successful screening trial is defined as ≥50% pain relief and satisfactory on table paraesthesia coverage (i.e. ≥80%) of the pain area or successful location of leads at anatomical target for paraesthesia free therapies. Patients with an unsuccessful screening trial will not be implanted but all participants continue to be followed-up to six-months.
Intervention: Implantation only strategy
In the implantation only strategy group, all participants with satisfactory on table paraesthesia coverage (i.e. ≥80%) of the pain area and no dislike of sensations, and satisfactory anatomical lead location for paraesthesia free devices would receive a permanent implant.
Patient outcome measures are collected at clinic visits at baseline (pre-randomisation), and at three and six-month follow-up measured from date of trial or permanent implant. The semi-structured interviews are carried out in a cohort of 32 subjects before and one-month following implantation or trial exit.
Intervention type
Other
Phase
Drug names
Primary outcome measure
Pain is measured on a Numerical Rating Scale (NRS) at 6 months, with a minimal clinically important difference (MCID) of 2 points between the two randomised treatment arms
Secondary outcome measures
1. The proportion of patients achieving at least 50% and 30% pain relief at 6 months, measured on the NRS at baseline, 3 and 6 months
2. Health related quality of life is measured using the EQ-5D-5L at baseline, 3 and 6 months
3. Function is measured using the Oswestry Disability Index (ODI) questionnaire at baseline, 3 and 6 months
4. Patient satisfaction is measured using the Patients’ Global Impression of Change (PGIC) questionnaire at 3 and 6 months
5. Complication rates are measured using Adverse Events recording at each visit
6. Patients' views of the screening trial, implantation and overall use of the device, assessed using a semi-structured interview for 30 patients (10 at each centre) at baseline and 1 month post implant by telephone
Overall trial start date
24/07/2015
Overall trial end date
31/05/2020
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Adults (≥18 years) who are clinically considered to be candidates for SCS as per NICE TA159
2. Pain of neuropathic nature of an intensity of at least 5 as assessed on a numerical rating scale (NRS)
3. Patient has persistent pain for more than 6 months despite appropriate conventional medical and surgical management including (TENS), acupuncture, oral analgesic agents, cognitive behavioural therapy as well as nerve blockade where appropriate
4. Satisfactory multidisciplinary assessment by a team with expertise in delivering SCS therapy
5. Capable of providing informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 100; UK Sample Size: 100
Participant exclusion criteria
1. Patient refusal to participate in the study
2. Presence of an on-going pain condition considered by the investigator to overshadow the neuropathic pain condition to be treated with SCS
3. Current or previous treatment with an implanted pain relief device
4. Current participation or planned participation in other studies that may confound the results of this study
5. Ongoing anticoagulation therapy, which cannot be safely discontinued
6. Poor cognitive ability
7. Unable to undergo study assessments or complete questionnaires independently
8. Patient is pregnant or planning to become pregnant during the course of the study
Recruitment start date
06/06/2017
Recruitment end date
01/01/2019
Locations
Countries of recruitment
United Kingdom
Trial participating centre
The James Cook University Hospital
Cheriton House
Marton Road
Middlesbrough
TS4 3BW
United Kingdom
Trial participating centre
Basildon and Thurrock University Hospital
Nethermayne
Basildon
SS16 5NL
United Kingdom
Trial participating centre
Seacroft Hospital
York Road
Leeds
LS14 6UH
United Kingdom
Funders
Funder type
Government
Funder name
National Institute for Health Research
Alternative name(s)
NIHR
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
The trialists are currently in the process of preparing the protocol publication. Following this they intend to publish the results in a high impact peer reviewed journal. In addition they also intend to present findings at national and International conferences as appropriate.
IPD sharing statement:
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.
Intention to publish date
31/05/2021
Participant level data
Other
Basic results (scientific)
Publication list